BioLine Rx (BioLine Rx) Accounts Receivable : $0.36 Mil (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. BioLine Rx's accounts receivables for the quarter that ended in Dec. 2023 was $0.36 Mil.

Accounts receivable can be measured by Days Sales Outstanding. BioLine Rx's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 6.81.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. BioLine Rx's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.09.

BioLine Rx Accounts Receivable Historical Data

The historical data trend for BioLine Rx's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Accounts Receivable Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

0.36

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	0.36

BioLine Rx Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

BioLine Rx Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

BioLine Rx's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.358	/	4.8	*	91
=	6.81

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), BioLine Rx's accounts receivable are only considered to be worth 75% of book value:

BioLine Rx's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(42.994	+	0.75 * 0.358	+	0.5 * 1.953	-	50.702
-	0	-	0)	/	72.4393
=	-0.09

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

BioLine Rx Accounts Receivable Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.